Moderna or BioNTech, but for discovering precision cancer medicines using a genetic screening platform.

A next-generation Blueprint Medicines or Loxo Oncology, specializing in finding cancer vulnerabilities through a unique approach called synthetic lethality.

• RP-3500 (camonsertib): An ATR inhibitor in clinical development for the treatment of solid tumors with specific genetic alterations such as ATM mutations.
• RP-6306: A PKMYT1 inhibitor being investigated for its potential to treat solid tumors with specific genetic alterations like CCNE1 amplification.
• Lunresertib (RP-9036): A Polθ inhibitor in partnership with Roche, currently in Phase 1 clinical trials for advanced solid tumors.

Steve Forte, President, Chief Executive Officer & Chief Financial Officer

Mr. Forte was appointed President, CEO, and CFO of Repare Therapeutics in April 2025, having previously served as Executive Vice President and CFO since October 2019. Prior to joining Repare, he served as Chief Financial Officer of Clementia Pharmaceuticals Inc., which was acquired by Ipsen S.A. for $1.3 billion. He also previously served as Chief Financial Officer of Thinking Capital Financial Corporation, a Canadian financial technology firm, where he ultimately led the firm through a sale to Purpose Investments. Mr. Forte held various financial leadership roles at Aptalis Pharma Inc. and CST Canada Co. from 2005 to 2015.

Michael Zinda, Ph.D., Executive Vice President & Chief Scientific Officer

Dr. Zinda serves as the Executive Vice President and Chief Scientific Officer at Repare Therapeutics. His prior experience includes serving as executive director of Cancer Biosciences at AstraZeneca.

Maria Koehler, M.D., Ph.D., Executive Vice President & Chief Medical Officer

Dr. Koehler is the Executive Vice President and Chief Medical Officer at Repare Therapeutics. Her previous roles include serving as Chief Medical Officer of Bicycle Therapeutics and Vice President of Strategy for Pfizer Oncology.

Daniel Bélanger, Executive Vice President, Human Resources

Mr. Bélanger joined Repare Therapeutics as Executive Vice President, Human Resources in May 2023. He brings 25 years of global Human Resources experience within the life science industry, having previously served as Chief Human Resources Officer at another company and held progressive global leadership roles in Human Resources for 17 years at Aptalis Pharma, formerly Axcan Pharma.

Sandra Alves, Chief Accounting Officer

Ms. Alves has been promoted to Chief Accounting Officer at Repare Therapeutics. Prior to this role, she served as Vice President and Corporate Controller at the company.

The key risks to Repare Therapeutics (RPTX) are primarily associated with the inherent challenges of a clinical-stage biotechnology company, its financial sustainability, and broader market dynamics.

1. Clinical Trial Outcomes and Regulatory Approval: As a clinical-stage oncology company, Repare Therapeutics' success hinges on the outcomes of its ongoing and future clinical trials. There is a significant risk that positive results observed in preclinical testing and earlier clinical trials may not be replicated in later-stage trials, or that the data generated may not be sufficient to demonstrate the efficacy and safety of a product candidate to regulatory authorities. Disappointing results from pivotal trials, such as POLAR and LIONS, could significantly impact the company's prospects. The uncertainties and timing associated with the regulatory approval process also pose a substantial risk.
2. Need for Additional Funding: Repare Therapeutics requires substantial additional capital to finance its operations and advance its pipeline. While the company benefits from collaboration and licensing agreements, and potential milestone payments can provide non-dilutive funding, the sustainability and realization of these revenues are not guaranteed. A potential increase in research and development (R&D) and operational expenses could necessitate raising capital through equity markets sooner than anticipated, potentially leading to dilution for existing shareholders. The company recently undertook a significant workforce reduction of approximately 75% to extend its cash runway, indicating existing financial pressures.
3. Competition and Macroeconomic Conditions: Repare Therapeutics operates in a highly competitive biopharmaceutical landscape, facing risks from changes in expected or existing competition. Furthermore, broader macroeconomic conditions, including fluctuations in inflation, uncertain credit and financial markets, and geopolitical events (such as conflicts in Ukraine and the Middle East), can adversely impact the company's business, its ability to conduct clinical trials, and its overall financial position.

Repare Therapeutics (symbol: RPTX) is a clinical-stage precision oncology company with several main product candidates in its pipeline.

For their product candidates, the addressable markets are identified as follows:

• Lunresertib (RP-6306): This is a PKMYT1 inhibitor. The global PKMYT1 inhibitors market was valued at USD 90.2 million in 2024 and is projected to grow to USD 1.1 billion by 2035, with a Compound Annual Growth Rate (CAGR) of 25.7% from 2025 to 2030.
• Camonsertib (RP-3500): This is an ATR inhibitor. The global ATR Kinase Inhibitor market size reached USD 1.24 billion in 2024 and is expected to grow to USD 5.13 billion by 2033, expanding at a CAGR of 17.8% from 2025 to 2033.
• RP-1664: This is a PLK4 inhibitor designed to target TRIM37-high solid tumors, including neuroblastoma and breast cancer. A specific addressable market size for "TRIM37-high solid tumors" or for PLK4 inhibitors in monetary terms could not be identified.
• RP-3467: This is a Polθ ATPase inhibitor associated with BRCA mutations and other genomic alterations, targeting molecularly selected advanced solid tumors such as ovarian, breast, metastatic castration-resistant prostate, and pancreatic adenocarcinoma. The global BRCA Mutations Treatment Market was valued at approximately USD 4.37 billion in 2023 and is projected to reach USD 4.88 billion in 2024. The global BRCA Mutation-Positive Ovarian Cancer Market was valued at USD 1874.78 million in 2024 and is expected to increase to USD 3607.17 million by 2031, growing at a CAGR of 9.8%. North America accounts for over 38% of this global market. Additionally, the global market for Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Genes, which RP-3467 targets, was USD 5.62 billion in 2022 and is expected to reach USD 11.28 billion by 2030, with a CAGR of 9.10% during the forecast period from 2023 to 2030.

• Milestone Payments and Royalties from Licensing Agreements: Repare Therapeutics generates revenue through collaboration and license agreements with larger pharmaceutical partners, receiving upfront payments, milestone payments tied to research, development, and regulatory progress, and potential future royalties on product sales. A significant driver will be the exclusive worldwide licensing agreement with Debiopharm for lunresertib (a first-in-class PKMYT1 inhibitor), signed in July 2025. This agreement includes a $10 million upfront payment and eligibility for up to $257 million in potential clinical, regulatory, commercial, and sales milestones, as well as single-digit royalties on global net sales.
• Advancement and Potential Commercialization of Clinical Pipeline (RP-1664 and RP-3467): The company has reprioritized its clinical portfolio to focus on advancing three ongoing Phase 1 clinical trials: RP-1664 (LIONS trial, a PLK4 inhibitor) and RP-3467 (POLAR trial, a Polθ ATPase inhibitor), and lunresertib in combination with Debiopharm's WEE1 inhibitor, Debio 0123. Initial data readouts for the LIONS and POLAR trials are expected in the fourth quarter of 2025. Positive clinical trial results for these candidates could trigger further milestone payments from existing or new partnerships and pave the way for future commercialization, thereby contributing to revenue growth.
• New Strategic Partnerships and Out-licensing Opportunities: Repare is actively exploring strategic alternatives and partnerships across its portfolio to enhance long-term shareholder value. This includes seeking partnering opportunities for programs like the lunresertib and camonsertib combination. Any new collaboration agreements for its innovative pipeline assets, particularly those utilizing its proprietary SNIPRx® platform, could lead to additional upfront payments and milestone revenues.

Share Issuance

• Repare Therapeutics had significant capital stock issuances of $247.84 million in 2020 and $95.56 million in 2021, likely associated with its initial public offering in 2020.
• Smaller capital stock issuances were reported at $0.88 million in 2022, $0.84 million in 2023, and $0.54 million in 2025.
• The number of shares outstanding increased by 0.92% year-over-year as of October 28, 2025.

Inbound Investments

• The company entered into an exclusive worldwide licensing agreement with Debiopharm for lunresertib, receiving a $10 million upfront payment and up to $257 million in potential milestone payments and royalties.
• Repare Therapeutics out-licensed discovery platforms to DCx Biotherapeutics, which included a $1 million upfront payment, $3 million in near-term payments, 9.99% equity, anti-dilution rights, and future milestones.
• A collaboration with Bristol Myers Squibb was established (mentioned in 2020 filings) to leverage Repare's SNIPRx platform for the discovery and development of oncology medicines.

Capital Expenditures

• Capital expenditures were reported as $0 in the last 12 months (prior to late 2024/early 2025), indicating minimal spending on long-term assets during this period.
• The company's primary focus for capital allocation is on advancing its clinical-stage precision oncology pipeline, which includes candidates like lunresertib, camonsertib, RP-1664, and RP-3467.